Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial".
Press Release Nov 14 2025
Filed with NSE · · 2 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 13 2025
- Press Release Nov 11 2025
- Press Release Nov 07 2025
- Press Release Nov 06 2025
- Press Release Nov 05 2025
Later from Zydus Lifesciences
- Press Release Nov 25 2025
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 26 2025
- Press Release Nov 27 2025
- Press Release Dec 04 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences